Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

8.130 +0.140 (+1.75%)
Streaming Delayed Price Updated: 2:24 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
A Preview Of Ocular Therapeutix's Earnings ↗
Ocular Therapeutix (NASDAQ:OCUL) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ocular... 
Via Benzinga
News headline image
Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market ↗
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. 
Via InvestorPlace
News headline image
Nike, Lululemon, Dick's Sporting Goods And Other Big Losers From Friday ↗
U.S. stocks closed lower with the Dow Jones dropping 500 points on Friday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
Recap: Ocular Therapeutix Q2 Earnings ↗
  Ocular Therapeutix (NASDAQ:OCUL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday ↗
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
News headline image
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
News headline image
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea ↗
 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket ↗
Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem... 
Via Benzinga
News headline image
Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 8, 2022 ↗
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter. 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
News headline image
Expert Ratings for Ocular Therapeutix ↗
Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding... 
Via Benzinga
News headline image
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 9, 2022 ↗
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
News headline image
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.